{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:11Z","timestamp":1787034311212,"version":"build-2736575974"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor-associated macrophages (TAMs) play a critical role in lung cancer progression, immune evasion, and treatment resistance within the unique, tissue-specific pulmonary immune microenvironment. However, a comprehensive bibliometric synthesis combining multi-database validation, quantitative time-series forecasting, and clinical translation integration remains lacking in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following a PRISMA-compliant two-stage screening protocol, literature published between 2005 and 2025 was retrieved from the Web of Science Core Collection (WOSCC) and Scopus. Bibliometric mapping and keyword clustering were performed using VOSviewer (v1.6.20), CiteSpace (v7.0.0), and Bibliometrix (v4.1.2). Predictive modeling of future annual output was conducted using an Auto-Regressive Integrated Moving Average (ARIMA) time-series framework. Methodological quality and network integrity were evaluated using CiteSpace structural metrics (Modularity Q and Mean Silhouette S).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Annual output increased slowly from 2005 to 2015 and accelerated sharply after 2018, reaching 439 articles in 2025, and is projected to reach 455 articles (95% CI 428-482) in 2026. China led in publication volume (1,970 articles in WOSCC) while the United States had the highest citation impact. Keyword clustering revealed a thematic progression from early genetic susceptibility and chemotherapy-related studies, through TAM polarization and metabolic reprogramming, to recent emphasis on lung adenocarcinoma, immune infiltration, and immunotherapy combinations. Citation bursts highlighted PD-1 expression on TAMs and recent interest in macrophage polarization. Fragmentary clusters on sarcopenia and animal models suggest underdeveloped but clinically relevant niches. Major funding came from the National Natural Science Foundation of China and the US National Cancer Institute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lung cancer TAM research has moved from descriptive phenotyping toward mechanisms of heterogeneity, metabolism, and chemokine-driven immune regulation. Immunotherapy combinations and spatial technologies are current frontiers, but translational bottlenecks persist: lack of standardized TAM subset nomenclature, limited clinical validation, and neglect of small cell lung cancer. Cross-institutional collaboration and rigorous clinical testing are needed to bridge the gap between mechanistic discovery and patient benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1900522","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:20Z","timestamp":1787031380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From description to prediction: a multi-database bibliometric forecast-validation study of lung cancer and tumor-associated macrophages research (2005\u20132025)"],"prefix":"10.3389","volume":"17","author":[{"given":"Tao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsong","family":"Zeng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/curroncol32030146","article-title":"Lung cancer: Targeted therapy in 2025","volume":"32","author":"Bouchard","year":"2025","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31060258","article-title":"A review of immunotherapy in non-small-cell lung cancer","volume":"31","author":"Capella","year":"2024","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo5570","article-title":"Immunogenomic cancer evolution: A framework to understand cancer immunosuppression","volume":"10","author":"Kumagai","year":"2025","journal-title":"Sci Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv211","article-title":"Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non-small cell lung cancer","volume":"107","author":"Gentles","year":"2015","journal-title":"J Natl Cancer Institute"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: An effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping polarization of tumor-associated macrophages in\u00a0cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells14100741","article-title":"Tumor-associated macrophages: Polarization, immunoregulation, and immunotherapy","volume":"14","author":"Saeed","year":"2025","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189344","article-title":"Interactions between cancer cells and tumor-associated macrophages in tumor microenvironment","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156082","article-title":"Heterogeneity of tumor-associated macrophages in colorectal cancer: Origins, classification, and immunotherapeutic implications","volume":"272","author":"Li","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s552449","article-title":"Tumor-associated macrophages in lung cancer: Origins, functional heterogeneity, and therapeutic implications","volume":"18","author":"Tao","year":"2025","journal-title":"J Inflammation Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.34133\/research.0851","article-title":"SPP1(+) TAM: CD8(+) T cell crosstalk associates with blocking radiotherapy efficacy in lung cancer","volume":"8","author":"Jin","year":"2025","journal-title":"Res (Washington DC)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12672-026-05095-w","article-title":"Multi-omics reveals SPP1\u2009+\u2009malignant and CXCR4+ TAM crosstalk predicts immunotherapy response in\u00a0lung adenocarcinoma","volume":"17","author":"Wang","year":"2026","journal-title":"Discover Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00262-025-04180-3","article-title":"Single-cell transcriptomic analyses provide insights into SPP1(+) TAM-mediated immune suppression and CD8(+) T cell dysfunction in lung cancer","volume":"74","author":"Almgrami","year":"2025","journal-title":"Cancer Immunology Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41419-023-06021-6","article-title":"Single-cell profiling reveals the trajectory of FOLR2-expressing tumor-associated macrophages to regulatory T cells in the progression of lung adenocarcinoma","volume":"14","author":"Xiang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: Can we be more clever than cancer cells","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221472","article-title":"Phagocytosis increases an oxidative metabolic and immune suppressive signature in tumor macrophages","volume":"220","author":"Gonzalez","year":"2023","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756722","article-title":"Single-cell RNA sequencing reveals the heterogeneity of tumor-associated macrophage in non-small cell lung cancer and differences between sexes","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf253","article-title":"Transcriptional states of lung cancer microenvironment reveal macrophage subtype dynamics linked to disease progression","volume":"214","author":"Keremit\u00e7i","year":"2025","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1493250","article-title":"A bibliometric analysis of immunotherapy for atherosclerosis: Trends and hotspots prediction","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: A bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e42080","article-title":"Research trends and network approach of critical thinking skills in English language teaching - A bibliometric analysis implementing R studio","volume":"11","author":"Arthi","year":"2025","journal-title":"Heliyon"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2022.1434","article-title":"VOSviewer and bibliometrix","volume":"110","author":"Arruda","year":"2022","journal-title":"J Med Library Assoc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1401342","article-title":"Mechanisms of exercise intervention in type 2 diabetes: A bibliometric and visualization analysis based on CiteSpace","volume":"15","author":"Jin","year":"2024","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: A Cancer J For Clin"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet (London England)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211485","article-title":"Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses","volume":"334","author":"Anastasiou","year":"2011","journal-title":"Sci (New York NY)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature07623","article-title":"Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis","volume":"457","author":"Kim","year":"2009","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.003","article-title":"Effects of tobacco smoke on immunity, inflammation and autoimmunity","volume":"34","author":"Arnson","year":"2010","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet (London England)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: An update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3009","article-title":"ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: Results from a phase 1b\/2 study","volume":"28","author":"Johnson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: Results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4792","article-title":"A phase Ib\/II study of pepinemab in combination with avelumab in advanced non-small cell lung cancer","volume":"27","author":"Shafique","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0504-8","article-title":"RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer","volume":"121","author":"Morgensztern","year":"2019","journal-title":"Br J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200501-010ac","article-title":"Peroxisome proliferator-activated receptor-\u03b3 as a regulator of lung inflammation and repair","volume":"2","author":"Standiford","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"B59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/mcp.0b013e328013f47e","article-title":"Particulate matter in the environment: Pulmonary and cardiovascular effects","volume":"13","author":"Alfaro-Moreno","year":"2007","journal-title":"Curr Opin Pulmonary Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2005.11.021","article-title":"Dose-dependent influence of genetic polymorphisms on DNA damage induced by styrene oxide, ethylene oxide and gamma-radiation","volume":"219","author":"Godderis","year":"2006","journal-title":"Toxicology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.etp.2005.05.008","article-title":"Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach","volume":"57","author":"Castell","year":"2005","journal-title":"Exp Toxicologic Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70393-x","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9575-3","article-title":"Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer","volume":"28","author":"Luo","year":"2011","journal-title":"Med Oncol (Northwood London England)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1d23c","article-title":"A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer","volume":"5","author":"Cl\u00e9ment-Duch\u00eane","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125063","article-title":"Crude polysaccharide from Danggui Buxue decoction enhanced the anti-tumor effect of gemcitabine by remodeling tumor-associated macrophages","volume":"242","author":"Zhan","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2012.13.9.4373","article-title":"Impact of chemotherapy on hypercalcemia in breast and lung cancer patients","volume":"13","author":"Hassan","year":"2012","journal-title":"Asian Pacific J Cancer Prev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3143096","article-title":"Aerosol gemcitabine after amputation inhibits osteosarcoma lung metastases but not wound healing","volume":"2018","author":"Kleinerman","year":"2018","journal-title":"Sarcoma"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161024574","article-title":"Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma","volume":"16","author":"Sun","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.18","article-title":"Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association","volume":"35","author":"Yang","year":"2016","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/1759-7714.12148","article-title":"Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy","volume":"6","author":"Li","year":"2015","journal-title":"Thorac Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3279","article-title":"MiR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells","volume":"48","author":"Chu","year":"2016","journal-title":"Int J Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120426","article-title":"Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells","volume":"10","author":"Mi","year":"2015","journal-title":"PLoS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s164574","article-title":"Adenosquamous carcinoma of the lung","volume":"11","author":"Li","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101374","article-title":"Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy","volume":"12","author":"Shen","year":"2025","journal-title":"Genes Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/lctt.s55176","article-title":"Targeting PD-1\/PD-L1 in lung cancer: Current perspectives","volume":"6","author":"Gonz\u00e1lez-Cao","year":"2015","journal-title":"Lung Cancer (Auckland NZ)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1236681","article-title":"Novel immunotherapy in the treatment of advanced non-small cell lung cancer","volume":"9","author":"Santabarbara","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106088","article-title":"Current status and development of anti-PD-1\/PD-L1 immunotherapy for lung cancer","volume":"79","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1093277","article-title":"Small cell lung cancer: Recruitment of macrophages by circulating tumor cells","volume":"5","author":"Hamilton","year":"2016","journal-title":"Oncoimmunology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2017.01.003","article-title":"The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation","volume":"106","author":"Iriki","year":"2017","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/biology10060502","article-title":"Characterization of tumor-associated macrophages and the immune microenvironment in limited-stage neuroendocrine-high and -low small cell lung cancer","volume":"10","author":"Dora","year":"2021","journal-title":"Biology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c08032","article-title":"Nebulized therapy of early orthotopic lung cancer by iron-based nanoparticles: Macrophage-regulated ferroptosis of cancer stem cells","volume":"145","author":"Feng","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00324","article-title":"Macrophage and tumor cell cross-talk is fundamental for lung tumor progression: We need to talk","volume":"10","author":"Sarode","year":"2020","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13046-018-0878-0","article-title":"Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling","volume":"37","author":"Xu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14329","article-title":"Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer","volume":"13","author":"Duan","year":"2022","journal-title":"Thorac Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1042\/cs20180845","article-title":"Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers","volume":"133","author":"Katoh","year":"2019","journal-title":"Clin Sci (London England: 1979)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2022.03.016","article-title":"Tumor-associated CD163(+) macrophage as a predictor of tumor spread through air spaces and with CD25(+) lymphocyte as a prognostic factor in resected stage I lung adenocarcinoma","volume":"167","author":"Yoshida","year":"2022","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s531190","article-title":"Cinobufagin inhibits invasion and migration of non-small cell lung cancer via regulating glucose metabolism reprogramming in tumor-associated macrophages","volume":"19","author":"Sun","year":"2025","journal-title":"Drug Des Dev Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"PNAS"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.02.016","article-title":"Organ-level quorum sensing directs regeneration in hair stem cell populations","volume":"161","author":"Chen","year":"2015","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/cancers15082250","article-title":"The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages","volume":"15","author":"Matsubara","year":"2023","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8458","article-title":"CD86(+)\/CD206(+) tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma","volume":"8","author":"Sun","year":"2020","journal-title":"PeerJ"},{"key":"B94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00011-026-02196-8","article-title":"The characterization of RUNX1-mediated macrophage polarization requires a multidimensional perspective beyond the M1\/M2 binary","volume":"75","author":"Chen","year":"2026","journal-title":"Inflammation Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06298-x","article-title":"Patlak-Ki derived from ultra-high sensitivity dynamic total body [(18)F]FDG PET\/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-0069","article-title":"Spatial density and distribution of tumor-associated macrophages predict survival in non-small cell lung carcinoma","volume":"80","author":"Zheng","year":"2020","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14937","article-title":"Prognostic and predictive value of CD163 expression and the CD163\/CD68 expression ratio for response to adjuvant chemotherapy in patients with surgically resected lung squamous cell carcinoma","volume":"14","author":"Yanagawa","year":"2023","journal-title":"Thorac Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123840","article-title":"Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9625","article-title":"Inverse role of distinct subsets and distribution of macrophage in lung cancer prognosis: A meta-analysis","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-244","article-title":"Single-cell and spatial transcriptomics profile the interaction of SPP1(+) macrophages and FAP(+) fibroblasts in non-small cell lung cancer","volume":"14","author":"Xiao","year":"2025","journal-title":"Trans Lung Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf7777","article-title":"Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles","volume":"7","author":"Dick","year":"2022","journal-title":"Sci Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202351","article-title":"Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients","volume":"13","author":"Zhang","year":"2021","journal-title":"Aging"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-024-01032-8","article-title":"Single-cell analysis reveals the disparities in immune profiles between younger and elder patients","volume":"15","author":"Dong","year":"2024","journal-title":"Eur Geriatric Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2326-6066.cir-21-0326","article-title":"Macrophage-targeted therapy unlocks antitumoral cross-talk between IFN\u03b3-secreting lymphocytes and IL12-producing dendritic cells","volume":"10","author":"Pfirschke","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.1982","article-title":"Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin","volume":"7","author":"Pass","year":"2016","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01088-4","article-title":"A phase 1a\/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors","volume":"39","author":"Falchook","year":"2021","journal-title":"Invest New Drugs"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-025-03785-z","article-title":"Single-cell RNA sequencing reveals cellular and molecular heterogeneity in extensive-stage small cell lung cancer with different chemotherapy responses","volume":"25","author":"Gu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/jci81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2018.1444305","article-title":"Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK\/STAT3 signaling pathway in breast cancer","volume":"17","author":"Mu","year":"2018","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103209","article-title":"Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression","volume":"74","author":"Gu","year":"2024","journal-title":"Redox Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110171","article-title":"Macrophages are metabolically heterogeneous within the tumor microenvironment","volume":"37","author":"Geeraerts","year":"2021","journal-title":"Cell Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104555","article-title":"Macrophage CD5L is a target for cancer immunotherapy","volume":"91","author":"Sanchez-Moral","year":"2023","journal-title":"EBioMedicine"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1782545","article-title":"Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1(+)TAMs in immunotherapy response in non-small cell lung cancer","volume":"17","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396719","article-title":"Spatial interaction and functional status of CD68(+)SHP2(+) macrophages in tumor microenvironment correlate with overall survival of NSCLC","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01840-5","article-title":"SLC2A1(+) tumour-associated macrophages spatially control CD8(+) T cell function and drive resistance to immunotherapy in non-small-cell lung cancer","volume":"28","author":"Wang","year":"2026","journal-title":"Nat Cell Biol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.70138","article-title":"Diallyl trisulfide suppresses tumor-associated macrophage M2-like polarization and recruitment and improves the tumor microenvironment through blocking CCL5\/STAT3 signaling pathway against lung cancer","volume":"40","author":"Xie","year":"2026","journal-title":"Phytotherapy Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11630","article-title":"Tumor-associated macrophage-derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer","volume":"45","author":"Ma","year":"2021","journal-title":"Cell Biol Int"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.08.010","article-title":"E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1","volume":"491","author":"Pham","year":"2020","journal-title":"Cancer Lett"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400611","article-title":"CD147-K148me2-driven tumor cell-macrophage crosstalk provokes NSCLC immunosuppression via the CCL5\/CCR5 axis","volume":"11","author":"Wang","year":"2024","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15398","article-title":"PRPS2-mediated modulation of the antitumor immune response in lung cancer through CCL2-mediated tumor-associated macrophages and myeloid-derived suppressor cells","volume":"15","author":"Liu","year":"2024","journal-title":"Thorac Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1763652","article-title":"The CXCL9\/SPP1 polarity axis in tumor-associated macrophages: immunoregulatory and prognostic significance in non-small cell lung cancer","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318419","article-title":"Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade","volume":"68","author":"Zhu","year":"2019","journal-title":"Gut"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215795","article-title":"Dual inhibition of TGF\u03b2 signaling and CSF1\/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1","volume":"543","author":"Chen","year":"2022","journal-title":"Cancer Lett"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J Controlled Release"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cells11101652","article-title":"Induced CAR-macrophages as a novel therapeutic cell type for cancer immune cell therapies","volume":"11","author":"Su","year":"2022","journal-title":"Cells"},{"key":"B130","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:22Z","timestamp":1787031382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":130,"alternative-id":["10.3389\/fimmu.2026.1900522"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900522","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1900522"}}